Detection of metastatic insulinoma by positron emission tomography with [68Ga]exendin-4-A case report

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1519-1524

  Eriksson, Olof ^a   Velikyan, Irina ^a,b   Selvaraju, Ram K ^a   Kandeel, Fouad ^c   Johansson, Lars ^a,d   Antoni, Gunnar ^a,b   Eriksson, Barbro ^a   Sörensen, Jens ^b   Korsgren, Olle ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CHROMOGRANIN; CYTOKERATIN; EVEROLIMUS; EXENDIN 4 GA 68; FLUOROURACIL; GLUCOSE; INSULIN; STREPTOZOCIN; SYNAPTOPHYSIN; TRACER; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; DRUG WITHDRAWAL; ENDOSCOPIC ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULINOMA; LAPAROTOMY; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; PANCREAS RESECTION; PARAAORTIC LYMPH NODE; PET-CT SCANNER; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SPLENECTOMY; SWEDEN; TUMOR LOCALIZATION;

FEMALE; HUMANS; INSULINOMA; LIVER NEOPLASMS; LYMPH NODES; PANCREATIC NEOPLASMS;

EID: 84899991622     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3541     Document Type: Article

References (24)

1. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neu roendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392-3400.
2. Orlefors H, Sundin A, Eriksson B, et al. PET-guided surgery-high correlation between positron emission tomography with 11C-5-hydroxytryptophane (5-HTP) and surgical findings in abdominal neuroendocrine tumours. Cancers. 2012;4:100-112.
3. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
4. Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19: R163-R185.
5. Selvaraju RK, Velikyan I, Johansson L, et al. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labe led DO3A-exendin-4. J Nucl Med. 2013;54:1458-1463.
6. Brom M, Woliner-Van der Weg W, Joosten L, et al. Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin [publishe d online February 1, 2014]. Diabetologia. doi: 10.1007/s00125-014- 3166-3.
7. Eriksson O, Selvaraju RK, Johansson L, et al. Quantitative imaging of serotonergic biosynthesis and degradation in the end ocrine pancreas [published online February 13, 2014]. J Nucl Med. doi: 10.2967/jnumed.113.125187.
8. Velikyan I, Beyer GJ, L angström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-560.
9. Velikyan I, Xu H, Nair M, Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol. 2012;39:628-639.
10. Vanderveen K, Grant C. Insulinoma. Cancer Treat Res. 2010;153: 235-252.
11. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19: 783-798.
12. Jensen RT, Cadiot G, BrandiML,et al.ENETSconsensus guidelines for the management of patients with digestive neuro endocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119.
13. MaeckeHR,HofmannM,Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S-178S.
14. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomogra phy. J Clin Oncol. 2008;26:1489-1495.
15. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743.
16. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Galabelled exendin-3, anewagent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37:1345-1355.
17. Wild D, BéhéM, Wicki A, et al. [Lys40(Ahx-DTPA-111In)NH2] exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47: 2025-2033.
18. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-1067.
19. Kiesewetter DO, Gao H, Ma Y, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2012;39:463-473.
20. Wu H L iang S Liu S Pan Y Cheng D Zhang Y. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals Nucl Med Commun. 2013 34 701-708.
21. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
22. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
23. Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013;1:115-122.
24. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073-1078.